Claim Missing Document
Check
Articles

Found 2 Documents
Search

Evaluation of the Relationship Between Metformin Use and Kidney Function in Geriatric Patients Diagnosed with Type 2 Diabetes Mellitus in the Inpatient Ward of Level II Hospital Prof. Dr. J. A. Latumeten Ambon Maryanti Tuharea; Diana Laila Ramatillah
Eduvest - Journal of Universal Studies Vol. 5 No. 9 (2025): Eduvest - Journal of Universal Studies
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/eduvest.v5i9.52062

Abstract

Metformin is a first-line therapy for type 2 diabetes mellitus (Type 2 DM), but its primary excretion through the kidneys raises concerns about the risk of nephrotoxicity, particularly in geriatric patients. This study aims to assess the relationship between metformin use and renal function in geriatric patients with Type 2 DM at Prof. Dr. J. A. Latumeten Ambon Level II Hospital. This study used a retrospective and prospective observational design of 150 geriatric patients receiving metformin. Data were collected through medical records and questionnaires. Kidney function parameters are assessed through GFR values and creatinine levels. The results of the study showed that the majority of respondents were aged 66–74 years (88.7%), with a prevalence of metformin use of 100%. No significant association was found between the duration of metformin use and a drastic decline in kidney function (the average creatinine value remained < 1.3 mg/dL). However, comorbidities and age were found to be factors that affect kidney function more significantly. Metformin is relatively safe to use in geriatric patients with close monitoring of renal function. The decline in kidney function is more influenced by age factors and comorbidities than by the use of metformin itself.
Evaluation of Treatment Outcomes and Quality of Life of MDR-TB Patients at Raden Mattaher Hospital Jambi Nopridayanti Nopridayanti; Diana Laila Ramatillah; Melly Miranda; Herlambang Herlambang
Enrichment: Journal of Multidisciplinary Research and Development Vol. 3 No. 5 (2025): Enrichment: Journal of Multidisciplinary Research and Development
Publisher : International Journal Labs

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55324/enrichment.v3i5.498

Abstract

Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to TB control efforts in Indonesia, primarily due to its complex, long-term treatment and significant drug side effects. To date, there is no comprehensive evaluation data on treatment outcomes and quality of life of MDR-TB patients at Raden Mattaher Regional Hospital, Jambi Province. This study aims to evaluate treatment outcomes and health-related quality of life in MDR-TB patients, as well as to identify predictors influencing therapy outcomes. This study used an observational   design with a retrospective approach, analyzing medical records of MDR-TB patients from 2020 to 2024. The WHOQOL-BREF instrument was used to measure quality of life. Bivariate and multivariate analyses were conducted to evaluate the association between patient characteristics and treatment outcomes. Most MDR-TB patients demonstrated successful treatment outcomes, but quality of life in the physical (score 45.2) and environmental (score 48.5) domains was relatively low. Side effects of second-line drugs, such as nausea, neuropathy, and hearing loss, contributed to the low physical domain scores. Multivariate test results showed that comorbid diabetes mellitus (DM) was a significant predictor of treatment outcomes (p = 0.007). The quality of life of MDR-TB patients at Raden Mattaher Regional Hospital in Jambi remains low, primarily influenced by side effects of therapy and the presence of comorbidities such as DM, which have been shown to impact treatment outcomes. More integrated interventions between TB management and comorbidities are urgently needed. Patients should be educated about side effects and the importance of treatment adherence. Hospitals are advised to improve side effect monitoring and integrate comorbidity management.